HC Wainwright Issues Positive Forecast for AngioDynamics (NASDAQ:ANGO) Stock Price

AngioDynamics (NASDAQ:ANGO) had its price target boosted by HC Wainwright from $14.00 to $15.00 in a report published on Friday morning,Benzinga reports. They currently have a buy rating on the medical instruments supplier’s stock.

Separately, Canaccord Genuity Group cut their price objective on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, October 4th.

AngioDynamics Trading Down 4.9 %

ANGO opened at $12.30 on Friday. The company has a 50 day moving average of $8.23 and a 200 day moving average of $7.42. AngioDynamics has a 12 month low of $5.26 and a 12 month high of $13.13. The company has a market cap of $499.80 million, a PE ratio of -2.02 and a beta of 0.59.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.07. The company had revenue of $72.90 million during the quarter, compared to analysts’ expectations of $70.93 million. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The firm’s quarterly revenue was down .1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.05) earnings per share. Research analysts forecast that AngioDynamics will post -0.41 earnings per share for the current fiscal year.

Institutional Trading of AngioDynamics

Several institutional investors and hedge funds have recently modified their holdings of the business. Quarry LP grew its holdings in shares of AngioDynamics by 75.1% during the second quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock worth $37,000 after purchasing an additional 2,594 shares in the last quarter. CWM LLC grew its stake in AngioDynamics by 981.3% in the 3rd quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock worth $76,000 after buying an additional 8,832 shares in the last quarter. Mackenzie Financial Corp bought a new position in shares of AngioDynamics in the 2nd quarter worth $80,000. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of AngioDynamics during the 3rd quarter valued at $86,000. Finally, AE Wealth Management LLC bought a new stake in shares of AngioDynamics during the 2nd quarter worth $87,000. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.